Lancet
Audio Summaries

[¹⁷⁷Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial

Aug 6, 2026

The PSMAddition trial aimed to evaluate the efficacy and safety of combining [^177Lu]Lu-PSMA-617 with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer. The results indicated that this combination significantly improved radiographic progression-free survival compared to the control group, despite a higher incidence of adverse events, suggesting it may be a viable new treatment option for this patient population.

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial

Jul 31, 2026

The authors aimed to compare patient-reported recovery and clinical outcomes between minimally invasive coronary artery bypass grafting (MICS CABG) via small thoracotomy and traditional sternotomy CABG in patients with multivessel coronary artery disease. The study found that MICS CABG significantly improved physical recovery at one month post-surgery without compromising safety through 12 months, suggesting its potential benefit for appropriately selected patients.

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

Jul 30, 2026

This phase 2 trial aimed to evaluate the efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes. The results demonstrated significant reductions in HbA1c levels at all tested doses (6, 25, and 50 mg) compared to placebo, with a safety profile consistent with existing GLP-1 and amylin receptor agonists.

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

Jul 30, 2026

The authors aimed to evaluate the efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes. The phase 2 trial demonstrated that zenagamtide significantly reduced HbA1c levels compared to placebo across various doses, with a safety profile similar to existing GLP-1 and amylin therapies. Most adverse events were mild to moderate, primarily gastrointestinal, and no deaths occurred during the study.

Psoriasis

Jul 29, 2026

The authors aim to provide a comprehensive overview of psoriasis, a chronic immune-mediated skin disease affecting over 40 million people globally, and its associated comorbidities and psychosocial impacts. They explore the diverse clinical phenotypes of psoriasis, the underlying genetic and environmental risk factors, and recent advancements in understanding the disease's immunological mechanisms, particularly the IL-23-IL-17 axis, which have led to the development of targeted therapies.

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

Jul 29, 2026

The authors aimed to evaluate the efficacy and safety of deramiocel, a heart-derived cellular therapy, in patients with advanced Duchenne muscular dystrophy (DMD). In a phase 3, randomized, double-blind, placebo-controlled trial, they found that deramiocel significantly improved skeletal muscle function compared to placebo, with a safety profile similar to that of the control group. These results suggest that deramiocel may effectively slow disease progression in advanced DMD.

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

Jul 28, 2026

The authors aimed to evaluate the efficacy and safety of ralinepag, a selective prostacyclin IP receptor agonist, in treating pulmonary arterial hypertension (PAH) compared to placebo. The phase 3 trial found that ralinepag significantly reduced the risk of first clinical worsening events in PAH patients receiving contemporary background therapy, although it was associated with a higher rate of treatment discontinuations due to adverse events. These findings support ralinepag as a viable oral treatment option for PAH.

Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial

Jul 23, 2026

The study aimed to determine the safety and effectiveness of stepping down from intravenous antibiotics to oral amoxicillin or amoxicillin-clavulanate in children hospitalized with severe community-acquired pneumonia in sub-Saharan Africa, and to identify the shortest effective treatment duration. Results indicated that a step-down strategy to oral antibiotics after initial intravenous treatment, with a total duration of 4-5 days, was non-inferior to the WHO-recommended 5-day intravenous treatment, suggesting a potential for shorter antibiotic courses without compromising patient safety.

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial

Jul 22, 2026

This study aimed to compare the efficacy and safety of high-dose chemotherapy followed by autologous stem-cell transplantation (HCT-ASCT) versus non-myeloablative chemoimmunotherapy (R-DeVIC) as consolidation therapy in newly diagnosed primary CNS lymphoma (PCNSL) patients. The results demonstrated that HCT-ASCT significantly improved 3-year progression-free survival (78% vs. 51%) compared to R-DeVIC, establishing HCT-ASCT as the preferred consolidation strategy for eligible patients.

Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial

Jul 17, 2026

This study aimed to determine whether empirical treatment with valganciclovir improves survival in infants with severe HIV-associated pneumonia in Africa. The trial found that while there was no significant difference in mortality rates at 15 days or 12 months between those receiving valganciclovir and those who did not, the treatment was associated with a lower hazard of death over time, suggesting a potential benefit without increased adverse effects.